J Chris Kingswood1, Sergiusz Jozwiak2, Elena D Belousova3, Michael D Frost4, Rachel A Kuperman5, E Martina Bebin6, Bruce R Korf7, J Robert Flamini8, Michael H Kohrman9, Steven P Sparagana10, Joyce Y Wu11, Thomas Brechenmacher12, Karen Stein13, Noah Berkowitz13, John J Bissler14, David N Franz15. 1. Sussex Renal Unit, Royal Sussex County Hospital, Brighton, UK The Trafford Department of Renal Medicine, Royal Sussex County Hospital, Brighton BN2 5BE, UK. 2. Department of Child Neurology, The Children's Memorial Health Institute, Warsaw, Poland. 3. Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russia. 4. Minnesota Epilepsy Group, St. Paul, MN, USA. 5. Department of Neurology, Children's Hospital & Research Center Oakland, Oakland, CA, USA. 6. Department of Neurology, University of Alabama School of Medicine, Birmingham, AL, USA. 7. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA. 8. Children's Healthcare of Atlanta, Atlanta, GA, USA. 9. University of Chicago Medicine Comer Children's Hospital, Chicago, IL, USA. 10. Texas Scottish Rite Hospital for Children, Dallas, TX, USA. 11. Division of Pediatric Neurology, Mattel Children's Hospital UCLA, Los Angeles, CA, USA. 12. Novartis Pharmaceuticals S.A.S., Rueil-Malmaison, France. 13. Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA. 14. Present address: Division of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA Present address: Division of Nephrology, Le Bonheur Children's Hospital and University of Tennessee College of Medicine, Memphis, TN, USA. 15. Department of Pediatrics and Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Abstract
BACKGROUND: Tuberous sclerosis complex (TSC) is characterized by benign tumours in multiple organs, including the brain, kidneys, skin, lungs and heart. Our objective was to evaluate everolimus, an mTOR inhibitor, in the treatment of angiomyolipoma in patients with subependymal giant cell astrocytoma (SEGA) associated with TSC. METHODS: EXamining everolimus In a Study of Tuberous Sclerosis Complex-1 (NCT00789828), a prospective, double-blind, randomized, placebo-controlled, Phase 3 study, examined everolimus in treating SEGA associated with TSC. Patients with serial SEGA growth from pre-baseline to baseline scans were randomly assigned (2:1) to receive 4.5 mg/m(2)/day everolimus (target blood trough: 5-15 ng/mL; n = 78) or placebo (n = 39). Angiomyolipoma response rates were analysed in patients (n = 44) with target baseline angiomyolipoma lesions (≥1 angiomyolipoma; longest diameter ≥1.0 cm). An angiomyolipoma response rate, defined as the proportion of patients with confirmed angiomyolipoma response, was assessed by kidney CT or MRI screening at baseline, at 12, 24 and 48 weeks and annually. RESULTS:Angiomyolipoma response rates were 53.3% (16/30) and 0% (0/14) for everolimus- and placebo-treated patients, respectively. Angiomyolipoma reductions ≥50% in the sum of volumes of all target lesions were seen only in everolimus-treated patients (56.5, 78.3 and 80.0%) compared with placebo-treated patients (0% at each time point) at Weeks 12, 24 and 48, respectively. Greater percentages of everolimus-treated patients had angiomyolipoma reductions ≥30% at these same time points (82.6, 100 and 100% versus 8.3, 18.2 and 16.7% for everolimus versus placebo, respectively). CONCLUSIONS:Everolimus showed efficacy in reducing angiomyolipoma lesion volume in patients with SEGA associated with TSC.The trial is registered with ClinicalTrials.gov, number NCT00789828; http://clinicaltrials.gov/ct2/show/NCT00789828?term=EXIST-1&rank=1.
RCT Entities:
BACKGROUND:Tuberous sclerosis complex (TSC) is characterized by benign tumours in multiple organs, including the brain, kidneys, skin, lungs and heart. Our objective was to evaluate everolimus, an mTOR inhibitor, in the treatment of angiomyolipoma in patients with subependymal giant cell astrocytoma (SEGA) associated with TSC. METHODS: EXamining everolimus In a Study of Tuberous Sclerosis Complex-1 (NCT00789828), a prospective, double-blind, randomized, placebo-controlled, Phase 3 study, examined everolimus in treating SEGA associated with TSC. Patients with serial SEGA growth from pre-baseline to baseline scans were randomly assigned (2:1) to receive 4.5 mg/m(2)/day everolimus (target blood trough: 5-15 ng/mL; n = 78) or placebo (n = 39). Angiomyolipoma response rates were analysed in patients (n = 44) with target baseline angiomyolipoma lesions (≥1 angiomyolipoma; longest diameter ≥1.0 cm). An angiomyolipoma response rate, defined as the proportion of patients with confirmed angiomyolipoma response, was assessed by kidney CT or MRI screening at baseline, at 12, 24 and 48 weeks and annually. RESULTS:Angiomyolipoma response rates were 53.3% (16/30) and 0% (0/14) for everolimus- and placebo-treated patients, respectively. Angiomyolipoma reductions ≥50% in the sum of volumes of all target lesions were seen only in everolimus-treated patients (56.5, 78.3 and 80.0%) compared with placebo-treated patients (0% at each time point) at Weeks 12, 24 and 48, respectively. Greater percentages of everolimus-treated patients had angiomyolipoma reductions ≥30% at these same time points (82.6, 100 and 100% versus 8.3, 18.2 and 16.7% for everolimus versus placebo, respectively). CONCLUSIONS:Everolimus showed efficacy in reducing angiomyolipoma lesion volume in patients with SEGA associated with TSC.The trial is registered with ClinicalTrials.gov, number NCT00789828; http://clinicaltrials.gov/ct2/show/NCT00789828?term=EXIST-1&rank=1.
Authors: Nishita Kothary; Michael C Soulen; Timothy W I Clark; A J Wein; Richard D Shlansky-Goldberg; Peter B Crino; S William Stavropoulos Journal: J Vasc Interv Radiol Date: 2005-01 Impact factor: 3.464
Authors: Prasanna Sooriakumaran; Philippa Gibbs; Geoffrey Coughlin; Virginia Attard; Frances Elmslie; Christopher Kingswood; Jeremy Taylor; Cathy Corbishley; Uday Patel; Christopher Anderson Journal: BJU Int Date: 2009-06-02 Impact factor: 5.588
Authors: Joel S Katz; Hyman Frankel; Tracy Ma; David Zagzag; Benjamin Liechty; Bruria Ben Zeev; Michal Tzadok; Orrin Devinsky; Howard L Weiner; Jonathan Roth Journal: Childs Nerv Syst Date: 2017-01-10 Impact factor: 1.475
Authors: Paolo Curatolo; Marit Bjørnvold; Patricia E Dill; José Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna Jansen; Sergiusz Jóźwiak; J Christopher Kingswood; Katarzyna Kotulska; Alfons Macaya; Romina Moavero; Rima Nabbout; Bernard A Zonnenberg Journal: Drugs Date: 2016-04 Impact factor: 9.546
Authors: Florian Bardin; Olivier Chevallier; Aurélie Bertaut; Emmanuel Delorme; Morgan Moulin; Pierre Pottecher; Lucy Di Marco; Sophie Gehin; Eric Mourey; Luc Cormier; Christiane Mousson; Marco Midulla; Romaric Loffroy Journal: Quant Imaging Med Surg Date: 2017-02
Authors: Peter Janssens; Karen Van Hoeve; Liesbeth De Waele; Stéphanie De Rechter; Kathleen J Claes; Els Van de Perre; Karl Martin Wissing; Bert Bammens; Anna Jansen; Djalila Mekahli Journal: Pediatr Nephrol Date: 2018-07-09 Impact factor: 3.714
Authors: Carl E Allen; Theodore W Laetsch; Rajen Mody; Meredith S Irwin; Megan S Lim; Peter C Adamson; Nita L Seibel; D Williams Parsons; Y Jae Cho; Katherine Janeway Journal: J Natl Cancer Inst Date: 2017-05-01 Impact factor: 13.506
Authors: Neera Nathan; Ji-an Wang; Shaowei Li; Edward W Cowen; Mary Haughey; Joel Moss; Thomas N Darling Journal: J Am Acad Dermatol Date: 2015-09-11 Impact factor: 11.527